The global IgA Nephropathy Disease Treatment Market is at the forefront of addressing the growing burden of renal diseases worldwide. With a projected value surpassing USD 485 million by 2028, the ...

Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ~40% of type 1 and type 2 diabetic patients. It increases the risk of death ...

In their classification system, Tervaert et al. 1 divide diabetic nephropathy into four classes based on the presence of what they consider to be increasingly serious glomerular lesions ().The ...

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the decision to submit a Biologics License Application (BLA) in the U.S. for ...

The FDA has given breakthrough therapy designation to OMS721, a new treatment for the rare kidney disease immunoglobulin A (IgA) nephropathy. The news is a major boost for Seattle-based Omeros ...

Table 1. Diabetic Nephropathy Stages: Cutoff Values of Urine Albumin for Diagnosis and Main Clinical Characteristics Stages Albuminuria cutoff values (ref. 14) Clinical characteristics (ref. no.) ...

糖尿病肾病（DN）是糖尿病的严重并发症，以肾脏结构和功能改变为特征。天然产物迷迭香酸（RA）已被证明具有治疗作用，包括抗炎症和抗氧化应激，对肾脏损伤或功能障碍。该研究在单细胞水平上表征了肾脏对DN诱导的损伤和RA治疗的细胞反应的异质性。

Credit: Thinkstock Investigators attending ASN’s Kidney Week 2024 reported progress on a number of IgA nephropathy drug trials. IgA nephropathy trials of new and emerging therapies that target B ...

The following is a summary of “Association between different proportions of crescents and the progression of IgA nephropathy ...

Included in National Reimbursement Drug List (NRDL) - Significantly Boosting market Penetration and Driving Valuation Reassessment . HONG KONG, N ...